AR052168A1 - Emplasto transdermico con ligandos especificos de progesterona a ( prasl) como principio activo - Google Patents

Emplasto transdermico con ligandos especificos de progesterona a ( prasl) como principio activo

Info

Publication number
AR052168A1
AR052168A1 ARP050105301A ARP050105301A AR052168A1 AR 052168 A1 AR052168 A1 AR 052168A1 AR P050105301 A ARP050105301 A AR P050105301A AR P050105301 A ARP050105301 A AR P050105301A AR 052168 A1 AR052168 A1 AR 052168A1
Authority
AR
Argentina
Prior art keywords
prasl
polymer
transdemic
active ingredient
plaster
Prior art date
Application number
ARP050105301A
Other languages
English (en)
Inventor
Hans-Peter Podhaisky
Stefan Bracht
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR052168A1 publication Critical patent/AR052168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente se refiere a un emplasto transdémico con ligandos específicos de progesterona A (PRASL) como principio activo, compuesto por una capa de base, al menos una capa de adhesivo con contenido de principio activo que se adhiere a aquella, a base de un polímero de silicona, un polímero de poliisobuteno (PIB), un polímero de poliacrilato o un polímero en bloque de estireno con butadieno o isopreno (SBS o SIS), así como una película protectora separable. El emplasto terapéutico transdémico segun la presente que contiene PRASL, eventualmente también en combinacion con estrogenos, es apropiado para la terapia de reemplazo hormonal y el control de la fertilidad. Reivindicacion 1: Emplasto transdémico que contiene el principio activo de la formula general (1) en donde R1 y R2 son, de modo independiente entre sí, H o F, R3 es CH3 o CF3 y Ar es como se muestra en los restos de formulas (2) o sus derivados farmacéuticamente apropiados (ligandos específicos de la progesterona A, PRASL), caracterizado porque el emplasto transdémico está compuesto por una capa de base, al menos una capa de adhesivo que contiene principio activo que se adhiere a ella, a base de un polímero de silicona, un polímero en bloque de estireno con butadieno o isopreno (SBS o SIS), en donde el principio activo está contenido en una concentracion del 0,1-10%, respecto del peso total de la matriz de adhesivo, así como una película protectora separable.
ARP050105301A 2004-12-20 2005-12-16 Emplasto transdermico con ligandos especificos de progesterona a ( prasl) como principio activo AR052168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004062182A DE102004062182B4 (de) 2004-12-20 2004-12-20 Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff

Publications (1)

Publication Number Publication Date
AR052168A1 true AR052168A1 (es) 2007-03-07

Family

ID=35559357

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105301A AR052168A1 (es) 2004-12-20 2005-12-16 Emplasto transdermico con ligandos especificos de progesterona a ( prasl) como principio activo

Country Status (20)

Country Link
EP (1) EP1671626A1 (es)
JP (1) JP2008524144A (es)
KR (1) KR20070089241A (es)
CN (1) CN101102754A (es)
AR (1) AR052168A1 (es)
AU (1) AU2005318548A1 (es)
BR (1) BRPI0519143A2 (es)
CA (1) CA2591076A1 (es)
CR (1) CR9207A (es)
DE (1) DE102004062182B4 (es)
EA (1) EA200701222A1 (es)
IL (1) IL183935A0 (es)
MX (1) MX2007007418A (es)
NO (1) NO20073768L (es)
PA (1) PA8657401A1 (es)
PE (1) PE20060841A1 (es)
TW (1) TW200633732A (es)
UY (1) UY29263A1 (es)
WO (1) WO2006066788A1 (es)
ZA (1) ZA200705991B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589542A (en) * 2008-05-30 2012-10-26 Mylan Inc Transdermal drug delivery system comprising an active agent in amorphous form and polyvinylpyrrolidone
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
CN103893189B (zh) * 2012-12-26 2019-04-23 江苏康倍得药业股份有限公司 含雌二醇的药物组合物及其制备与应用
WO2020230760A1 (ja) * 2019-05-13 2020-11-19 東洋紡株式会社 フィルター用濾材およびフィルター

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2065311C (en) * 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
DE4309830C1 (de) * 1993-03-26 1994-05-05 Lohmann Therapie Syst Lts Wirkstoffpflaster für die Abgabe von Estradiol an die Haut
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
DE19830732B4 (de) * 1998-07-09 2008-11-13 Lts Lohmann Therapie-Systeme Ag Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung
DE19830649C2 (de) * 1998-07-09 2003-04-10 Lohmann Therapie Syst Lts Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DK1482925T3 (da) * 2002-03-11 2007-05-14 Bayer Schering Pharma Ag 5- (2-hydroxy-3 -'1 - (3-trifluormethylphenyl) cyclopropylpropionylamino) phtalid og relaterede forbindelser med progesteronreceptormoducerende aktivitet til anvendelse i fertilitetskontrol og hormonerstatningsterapi
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Also Published As

Publication number Publication date
DE102004062182B4 (de) 2007-06-06
CR9207A (es) 2007-11-23
EA200701222A1 (ru) 2007-12-28
UY29263A1 (es) 2006-06-30
EP1671626A1 (de) 2006-06-21
CN101102754A (zh) 2008-01-09
CA2591076A1 (en) 2006-06-29
DE102004062182A1 (de) 2006-06-29
MX2007007418A (es) 2007-08-17
BRPI0519143A2 (pt) 2008-12-30
TW200633732A (en) 2006-10-01
JP2008524144A (ja) 2008-07-10
WO2006066788A1 (de) 2006-06-29
KR20070089241A (ko) 2007-08-30
NO20073768L (no) 2007-07-19
AU2005318548A1 (en) 2006-06-29
IL183935A0 (en) 2007-10-31
ZA200705991B (en) 2009-01-28
PE20060841A1 (es) 2006-09-14
PA8657401A1 (es) 2006-07-03

Similar Documents

Publication Publication Date Title
CA2679535C (en) Amorphous drug transdermal systems, manufacturing methods, and stabilization
ES2733812T3 (es) Polímeros acrílicos que contienen silicona para composiciones de administración transdérmica de fármacos
HRP20100254T1 (hr) Transdermalni sustav za davanje gestodena
JP2013237691A (ja) 経皮的なドラッグデリバリーシステムにおける医薬品の損失及び送達を制御するための組成物及び方法
ATE497745T1 (de) Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
CA2896336C (en) Compositions and methods for transdermal delivery of non-steroidal anti-inflammatory agents
JPH04503357A (ja) ニコチンの経皮デリバリー用デバイス
NO313813B1 (no) Transdermale, terapeutiske systemer som inneholder seksualsteroider og anvendelser
NO303262B1 (no) FremgangsmÕte for fremstilling av et faststoffmatrikssystem for transdermal medikamentavlevering
AR052168A1 (es) Emplasto transdermico con ligandos especificos de progesterona a ( prasl) como principio activo
PE20070205A1 (es) Dispositivos de liberacion transdermica de farmacos que contienen drospirenona y metodos de liberacion de los mismos
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
AU2016244227B2 (en) Once-a-day replacement transdermal administration of fentanyl
TW201204333A (en) Medical patch
US20220023425A1 (en) Stretchable backing layers for transdermal drug delivery systems
TWI327074B (en) Ultra violet shielding patch
DOP2005000263A (es) Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo.
TW201803563A (zh) 包含哌醋甲酯或其鹽之經皮傳遞系統及其方法
GT200500376A (es) Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo
Ibarra de Palacios et al. Comparative study to evaluate skin irritation and adhesion of Estradot® and Climara® in healthy postmenopausal women
AU2011258146A1 (en) Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
Davis et al. Evaluation of the long-term safety of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo
AU2017279775A1 (en) Amorphous drug transdermal systems, manufacturing methods, and stabilization
JPWO2018052039A1 (ja) 貼付剤
JP2010254646A (ja) 貼付剤

Legal Events

Date Code Title Description
FA Abandonment or withdrawal